Portfolio
BrightEdge is assembling a portfolio of companies to attack cancer from every angle.
BrightEdge is assembling a portfolio of companies to attack cancer from every angle.
Freenome
More accurately detecting cancer at earlier stages and define the tumor type to help oncologists select the best available treatment
CellCentric
A research driven and patient-centric clinical stage, private biotechnology company pioneering small molecule inhibition of the twin proteins, p300/CBP
TailorMed
Harnessing technology to reduce financial hardships for patients and improve the financial performance of healthcare providers
Paradigm
Rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trails for all patients, while enhancing trial efficiency and reducing barriers to participation.
Immunitas Therapeutics
A first-in-class NK and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company's programs are derived from their platform, a cross-functional, highly integrated, single cell genomics approach that enables rapid target identification and validation in parallel with antibody discovery and engineering.
Nusano
Working to make cancer diagnosis and patient care methods more widely accessible, supporting health equity through its particle acceleration technology that supplies health care clinics with medical radioisotopes.
Mercy BioAnalytics
Developing the first and only test for early cancer detection based on analysis of single extracellular vesicles present in the blood at high-abundance.
Naveris
Improving outcomes for the millions of people at risk of developing viral cancers through novel molecular diagnostics that enable earlier cancer detection.
Alpheus Medical
Developing a sonodynamic therapy platform targeting solid body tumors, starting with glioblastoma
Auron Therapeutics
Auron seeks to reprogram cells to elicit tumor cell maturation and reprogram cancer tissue to a more normal pehnotype
Modifi Bio
Developing a novel oncology therapeutics platform that exploits DNA defects in a wide range of cancer cells, and which aims to disrupt conventional oncology drug development.
Clasp Therapeutics
Expanding the reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type.
Persephone Biosciences
Developing precision immunotherapies utilizing synthetic biology and companion diagnostics for unmet needs and more equitable treatment outcomes
Sonata Therapeutics
Developing a new class of therapeutics that reprogram diseased cells to release a defined array of signals that precisely coordinate multicellular networks to drive disease resolution.
(exited) Checkmate
Developing immunotherapies designed to recognize and destroy tumor cells
(exited) Lunit
AI-powered diagnostic tools for cancer screening and biomarkers that can predict and guide patient responses to cancer therapy
(exited) Tmunity
Developing diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body. The company is focused on treating cancer, their first three targets are prostate, myeloma and ovarian.
Sonata Therapeutics
The first company to build a platform to develop drugs in the new field of exoneural biology, translating the language of the peripheral nervous system to produce therapeutic breakthroughs and improve human health
(exited) Navigating Cancer
A healthcare IT platform that allows for patients and their families to submit patient reported outcomes data to their oncology center in real time through the Company’s bidirectional interface with the oncology center’s EHR. Navigating Cancer’s proprietary predictive algorithm, allows for patients to be triaged so that interventions can occur when needed and the Company also distributes the right educational content to patients that has proven to improve compliance and adherence rates, and patient outcomes.
(exited) Castle Biosciences
Develops and commercializes diagnostic and prognostic tests for dermatologic cancers. The tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions.
(exited) Vincere Health
Developing a breakthrough health engagement and prevention platform for the most complex, costly populations, and hardest to help low-income - starting with smoking cessation